**Supplemental Table 1. Exclusion criteria**

|  |  |
| --- | --- |
| (1) | Severe diabetes mellitus |
|  | -Fasting blood glucose: ≥200 mg/dL |
| (2) | Abnormal electrolyte metabolism |
|  | -Na: <125 mEq/L or ≥155 mEq/L |
|  | -K: <3.1 mEq/L or ≥5.5 mEq/L |
|  | -Ca: <8.0 mg/dL or ≥12.1 mg/dL |
| (3) | Liver enzymes |
|  | -AST: ≥2.5×ULN\* |
|  | -ALT: ≥2.5×ULN\* |
| (4) | Bile duct obstruction |
|  | -ALP: ≥2.5×ULN\* |
|  | -T-BIL: ≥3.0 mg/dL |
| (5) | Nephropathy |
|  | -CRE: ≥2 mg/dL |
|  | -BUN: ≥25 mg/dL |
| (6) | Abnormal amino acid metabolism |
| (7) | Hemophilia |
| (8) | Hypersensitivity to ingredients of the test solutions or control solutions |
| (9) | Hypoparathyroidism or hypothyroidism |
| (10) | Inflammatory bowel disease |
| (11) | Pregnant or breastfeeding |
| (12) | Underwent blood sampling or provided blood donation of more than 200 mL within 4 weeks before the informed consent.  Underwent blood sampling or provided blood donation of more than 400 mL, within 12 weeks (male) or 16 weeks (female) before the day of informed consent |
| (13) | Participated in a clinical trial or clinical study and received a drug within 16 weeks before the day of informed consent |
| (14) | Deemed unsuitable for inclusion in the study for any other reason based on assessment by the investigator or sub-investigator |

\* ULN: Upper Limit of Normal

AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; T-BIL, total bilirubin; CRE, creatinine; BUN, blood urea nitrogen.

**Supplemental table 2. Actual volumes of the Test and Control solutions administered**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | POD1 | POD2 | POD3 | POD4 | POD5 | POD6 | POD7 |
| Test solutions | |  |  |  |  |  |  |  |
|  | OPF-108-1 | 34.57±6.43  (34) | 35.73±6.70  (47) | 38.60±7.27  (19) | - | - | - | - |
|  | OPF-108-2 | - | - | 34.10±5.26  (27) | 36.00±6.51  (46) | 36.00±6.51  (46) | 34.18±8.37  (45) | 31.35±7.14  (43) |
| Control solutions | |  |  |  |  |  |  |  |
|  | ELN-1 | 36.21±8.03  (40) | 36.53±6.89  (55) | 37.35±7.60  (27) | - | - | - | - |
|  | ELN-2 | - | - | 35.73±6.16  (28) | 36.42±7.11  (54) | 36.39±7.02  (54) | 35.88±7.80  (54) | 30.92±6.80  (54) |

Data are means ± SD, mL/kg body weight (n)

**Supplemental table 3. Actual calories of the Test and Control solutions administered**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | POD1 | POD2 | POD3 | POD4 | POD5 | POD6 | POD7 |
| Test solutions | |  |  |  |  |  |  |  |
|  | OPF-108-1 | 19.36±3.60  (34) | 20.01±3.75  (47) | 21.62±4.07 (19) | - | - | - | - |
|  | OPF-108-2 | - | - | 27.96±4.32  (27) | 29.52±5.34  (46) | 29.52±5.34  (46) | 28.03±6.87  (45) | 25.71±5.86  (43) |
| Control solutions | |  |  |  |  |  |  |  |
|  | ELN-1 | 20.28±4.50  (40) | 20.46±3.86  (55) | 20.92±4.25  (27) | - | - | - | - |
|  | ELN-2 | - | - | 29.30±5.05  (28) | 29.86±5.83  (54) | 29.84±5.75  (54) | 29.42±6.40  (54) | 25.35±5.58  (54) |

Data are means ± SD, kcal/kg body weight (n)

**Supplemental table 4. Actual amino acid amounts of the Test and Control solutions administered**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | POD1 | POD2 | POD3 | POD4 | POD5 | POD6 | POD7 |
| Test solutions | |  |  |  |  |  |  |  |
|  | OPF-108-1 | 0.69±0.13  (34) | 0.71±0.13  (47) | 0.77±0.15 (19) | - | - | - | - |
|  | OPF-108-2 | - | - | 1.02±0.16  (27) | 1.08±0.20  (46) | 1.08±0.20  (46) | 1.03±0.25  (45) | 0.94±0.21  (43) |
| Control solutions | |  |  |  |  |  |  |  |
|  | ELN-1 | 0.72±0.16  (40) | 0.73±0.14  (55) | 0.75±0.15  (27) | - | - | - | - |
|  | ELN-2 | - | - | 1.07±0.18  (28) | 1.09±0.21  (54) | 1.09±0.21  (54) | 1.08±0.23  (54) | 0.93±0.20  (54) |

Data are means ± SD, g/kg body weight (n)